21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Financial News

I-Mab raises $220M in series C

I-Mab Biopharma (Shanghai, China) raised $220 million June 29 in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...
23:59 , Jun 21, 2018 |  BC Innovations  |  Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
02:09 , Feb 3, 2018 |  BioCentury  |  Strategy

Road to acquisition

Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
21:58 , Dec 15, 2017 |  BioCentury  |  Emerging Company Profile

CD38 hat trick

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates...
19:04 , Dec 15, 2017 |  BC Week In Review  |  Company News

Sanofi details R&D strategy

Sanofi (Euronext:SAN; NYSE:SNY) highlighted its R&D road map at its analyst meeting Dec. 13. The pharma plans to shift its focus to biologics from small molecules, to multi-targeting compounds from mono-targeting ones and to proprietary...
01:17 , Dec 14, 2017 |  BC Extra  |  Company News

Sanofi details R&D strategy, reports cSCC data for PD-1 inhibitor

Sanofi (Euronext:SAN; NYSE:SNY) highlighted its R&D road map at its analyst meeting Wednesday. The pharma plans to shift its focus to biologics from small molecules, to multi-targeting compounds from mono-targeting ones and to proprietary assets...